Mpox
There is one antiviral treatment and one vaccine against mpox authorised in the EU.
Antiviral treatment
Tecovirimat is a treatment authorised to treat mpox as well as smallpox and cowpox.
It works by interfering with a protein called VP37 that is found on the surface of the virus, slowing down the spread of infection.
For more information on Tecovirimat, how it works and how EMA assessed it, see:
Vaccine
Imvanex is a vaccine that has been authorised to protect adults against mpox disease since 22 July 2022. It is also authorised to protect against smallpox and vaccinia.
Imvanex contains a weakened form of a virus that is closely related to the smallpox and mpox viruses but does not cause disease in humans and cannot reproduce in human cells.
For more information on Imvanex, how it works and how EMA assessed it, see:
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
